Methods Data were pooled for participants with type 2 diabetes and established CV disease
or high CV risk in the SUSTAIN 6 and PIONEER 6 trials. Participants received sc …

Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …

Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …

2 METHODS Patients included in the SUSTAIN-6 trial had T2D and, those who were aged≥
50 years had prevalent CVD (defined as previous CV, cerebrovascular or peripheral …

OBJECTIVE To evaluate the cardiovascular effects of semaglutide by baseline glycated
hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects …

Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …

2 METHODS The SUSTAIN 6 (NCT01720446) trial design has been previously reported. 7
Adults living with T2D at high risk of a CV event were randomized to receive 0.5 or 1.0 mg …

Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …